莫纳什大学和ClinChoice合作了3年,利用澳大利亚的试验网络和全球专业知识加快癌症,免疫和代谢疾病试验. Monash University and ClinChoice partner for 3 years to speed cancer, immune, and metabolic disease trials using Australia’s trial network and global expertise.

莫纳什大学和美国的ClinChoice公司已经建立了为期三年的战略合作伙伴关系,以加速早期和晚期临床试验,重点是治疗瘤学,免疫学和代谢疾病. Monash University and U.S.-based ClinChoice Inc. have formed a three-year strategic partnership to accelerate early- and late-phase clinical trials, focusing on therapies for oncology, immunology, and metabolic diseases. 这项合作利用了莫纳什广泛的试验网络,支持澳大利亚约25%的试点,并通过15多个国家3000名全科医生和ClinChoice全球经验以及3,000项已完成研究覆盖450万患者. The collaboration leverages Monash’s extensive trial network—supporting about 25% of Australia’s trials and reaching 4.5 million patients through 3,000 GPs—and ClinChoice’s global experience in over 15 countries and 3,000 completed studies. 它们共同的目标是提高研究效率,加强学术界与行业之间的联系,并更快地为患者提供创新治疗. Together, they aim to improve research efficiency, strengthen academic-industry ties, and bring innovative treatments to patients faster.